Technology
Global Flow Cytometry Market to Reach USD 11.14 Billion by 2034 at 9% CAGR as Rising Adoption in Clinical Diagnostics, Growing Multiparameter Cell Analysis, and Advances in High-Parameter Flow Cytometry Accelerate Market Growth, Reports Maximize Market Research
Published
50 minutes agoon
By
PUNE, India, Sept. 23, 2026 /PRNewswire/ — The Global Flow Cytometry Market was valued at USD 5.13 Billion in 2025 and is projected to expand at a 9% CAGR from 2026 to 2034, reaching USD 11.14 Billion by 2034, according to a new analysis by Maximize Market Research.
Global Flow Cytometry Market
The Global Flow Cytometry Market Report 2025 provides a detailed analysis of market trends, growth drivers, technological advancements, clinical applications, research activities, product innovations, regulatory developments, competitive developments, applications, and market forecasts through 2034. The market covers Instruments, Reagents and Consumables, Software, and Services across Cell-based Flow Cytometry and Bead-based Flow Cytometry, with applications spanning academic and research institutes, hospitals and clinical testing laboratories, and pharmaceutical and biotechnology companies.
The growing adoption of flow cytometry in clinical diagnostics, oncology, immunology, cell biology, drug discovery, and life science research is supporting the expansion of the global flow cytometry market. Increasing demand for multiparameter cellular analysis, immunophenotyping, biomarker identification, cell-cycle analysis, and immune-cell characterization is strengthening the use of flow cytometry across research and clinical environments. Rising investments in biotechnology, pharmaceutical R&D, precision medicine, and cell-based research are further contributing to demand for advanced flow cytometry systems, reagents, consumables, and analytical software.
Advancements in spectral flow cytometry, high-parameter analysis, automated workflows, cell sorting, nanoscale particle analysis, and AI-enabled data interpretation are further transforming the flow cytometry landscape. Increasing research into cancer, immunotherapy, stem cells, cell and gene therapies, and single-cell analysis is creating new opportunities for market participants. Product launches, technological innovation, strategic collaborations, acquisitions, and expansion of clinical and research applications are expected to strengthen the global flow cytometry market through 2034.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/29653/
Global Flow Cytometry Market gains momentum as rising adoption in clinical diagnostics and life science research, increasing demand for multiparameter cell analysis, advances in spectral and high-parameter flow cytometry, automation, and expanding cell and gene therapy applications accelerate technological innovation: Maximize Market Research unveils key insights.
Global Flow Cytometry Market Size & Forecast
Parameter
Value
Market Size (Base Year 2025)
USD 5.13 Billion
Forecast Market Size (2034)
USD 11.14 Billion
CAGR (2026-2034)
9 %
Base Year
2025
Forecast Period
2026-2034
Historical Period
2020-2025
Global Flow Cytometry Market Trends & Insights
North America leads the Global Flow Cytometry Market, supported by advanced healthcare infrastructure, strong biomedical research activity, established pharmaceutical and biotechnology industries, and extensive adoption of flow cytometry in clinical diagnostics and life science research.Asia-Pacific represents a high-growth region, driven by expanding pharmaceutical and biotechnology sectors, improving healthcare infrastructure, increasing biomedical research investments, and growing adoption of advanced cellular analysis technologies across China, Japan, India, and South Korea.Rising demand for multiparameter cellular analysis is increasing the adoption of flow cytometry across oncology, immunology, drug development, cell biology, and clinical diagnostics, particularly for immunophenotyping, biomarker identification, cell-cycle analysis, and immune-cell characterization.Spectral and high-parameter flow cytometry technologies are gaining importance, supported by the need for detailed analysis of complex and heterogeneous cell populations. Advances in automation, cell sorting, nanoscale particle analysis, and integrated data-analysis software are further expanding technology adoption.Clinical research and cell-based therapy development are accelerating market innovation, with increasing applications in cancer research, immunotherapy, stem-cell studies, and cell and gene therapy. Product launches, technological advancements, R&D investments, and development of automated analytical workflows are creating new opportunities for flow cytometry market participants.
Growing Adoption of Multiparameter Cellular Analysis Drives Market Growth
The increasing use of flow cytometry in clinical diagnostics, oncology, immunology, cancer research, drug discovery, cell biology, and life science research is driving market growth. Rising demand for immunophenotyping, biomarker identification, cell-cycle analysis, immune-cell characterization, and high-resolution cellular analysis is encouraging laboratories to adopt advanced flow cytometers. The expanding use of flow cytometry in pharmaceutical R&D, biotechnology research, immunotherapy, stem-cell studies, and cell-based research is further supporting demand for instruments, reagents, consumables, software, and services.
High Capital and Operating Costs Restrain Market Growth
The substantial investment required for advanced flow cytometry instruments, lasers, detectors, reagents, specialized software, maintenance, laboratory infrastructure, and technical support can restrict adoption, particularly among smaller hospitals, academic laboratories, and research facilities with limited budgets. The increasing complexity of high-parameter and spectral flow cytometry systems, together with recurring consumable and maintenance requirements, can further increase the overall cost of ownership and limit adoption in cost-sensitive markets.
Expansion of Spectral Flow Cytometry and Cell-Based Therapies Creates Opportunities
Advancements in spectral flow cytometry, high-parameter analysis, automated workflows, cell sorting, nanoscale particle analysis, and advanced data-analysis software are creating significant opportunities in the flow cytometry market. Growing applications in single-cell analysis, immunotherapy, cancer research, stem-cell studies, and cell and gene therapy are increasing demand for technologies capable of characterizing complex cell populations at greater resolution. The development of AI-enabled analysis, workflow automation, integrated software solutions, and application-specific platforms is further expanding opportunities for technology providers.
Shortage of Skilled Professionals and Complex Data Interpretation Create Challenges
The increasing complexity of multiparameter and high-dimensional flow cytometry datasets creates challenges related to panel design, compensation, quality control, instrument operation, data management, and interpretation. Laboratories require skilled professionals with expertise in flow cytometry instrumentation, fluorescence analysis, cell sorting, assay development, and computational data analysis. The shortage of trained personnel, together with the complexity of analyzing multidimensional cellular datasets and maintaining standardized workflows, can create operational challenges for clinical and research laboratories.
Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/29653/
Global Flow Cytometry Market Segmentation
The Global Flow Cytometry Market is segmented by Component, Technology, End Use, and Region. Increasing adoption of multiparameter cellular analysis, growing applications in clinical diagnostics and life science research, technological advancements in spectral and high-parameter flow cytometry, rising pharmaceutical and biotechnology R&D investments, and expanding applications in cell-based therapies are supporting market development across these segments.
Segmentation
Sub-Segments
By Component
Instruments; Reagents and Consumables; Software; Services
By Technology
Cell-based Flow Cytometry; Bead-based Flow Cytometry
By End Use
Academic & Research Institutes; Hospitals & Clinical Testing Laboratories;
Pharmaceutical & Biotechnology Companies
By Region
North America; Europe; Asia Pacific; Middle East & Africa; South America
North America Leads the Flow Cytometry Market While Asia Pacific Emerges as a High-Growth Region
North America held the largest share of the Global Flow Cytometry Market in 2025, supported by advanced healthcare infrastructure, strong biomedical research activity, established pharmaceutical and biotechnology industries, and widespread adoption of advanced cellular analysis technologies. The United States represents a major market due to substantial healthcare and life science investments, extensive clinical laboratory networks, strong oncology and immunology research, and increasing use of flow cytometry in clinical diagnostics, drug discovery, immunotherapy, and cell-based research. Canada and Mexico also contribute through improving laboratory infrastructure, expanding research capabilities, and growing adoption of advanced flow cytometry systems.
Europe represents an important market, supported by established healthcare systems, strong clinical and academic research networks, pharmaceutical and biotechnology activity, and increasing use of flow cytometry in diagnostic and research applications. The United Kingdom, France, Germany, Italy, Spain, Sweden, Austria, and other European markets are witnessing continued adoption of multiparameter flow cytometry, spectral flow cytometry, cell sorting, immunophenotyping, and advanced data-analysis technologies. Growing investments in precision medicine, immunology, cancer research, and cell-based therapies are further supporting regional market development.
Asia Pacific is expected to witness strong growth as pharmaceutical and biotechnology industries expand alongside improvements in healthcare infrastructure and biomedical research capabilities. China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, and other regional markets are contributing to market development. Rising investments in cancer research, drug development, immunology, cell biology, cell and gene therapies, and life science research, together with increasing adoption of high-parameter and automated flow cytometry systems, are creating opportunities across the region.
Middle East & Africa is gradually developing as healthcare modernization, laboratory infrastructure development, and investment in advanced diagnostic and research capabilities increase. South Africa, GCC countries, Egypt, Nigeria, and other regional markets are contributing to market development through expanding clinical laboratories, biomedical research activities, and increasing access to advanced analytical technologies. Growing demand for clinical diagnostics, immunological testing, and specialized laboratory analysis is supporting the gradual adoption of flow cytometry.
South America is supported by improving healthcare infrastructure, expanding research activities, and increasing adoption of advanced diagnostic and laboratory technologies. Brazil represents an important regional market, while Argentina and other South American countries are contributing as pharmaceutical and biotechnology capabilities develop and demand increases for sophisticated cell analysis, immunophenotyping, oncology research, and clinical laboratory testing.
Leading Companies Strengthen the Flow Cytometry Technology Landscape
Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Danaher Corporation, Agilent Technologies, Luminex Corporation, Miltenyi Biotec GmbH, Bio-Rad Laboratories Inc., Merck KGaA, Sysmex Corporation, Sony Biotechnology Inc., Cytek Biosciences Inc., Bio-Techne Corporation, BioLegend Inc., and Sartorius AG are among the prominent companies associated with the global flow cytometry landscape. Their activities across flow cytometers, cell sorters, reagents and consumables, spectral flow cytometry, software, automation, and cell-analysis solutions are supporting technological development and commercialization. Companies are also focusing on product launches, R&D, strategic collaborations, acquisitions, workflow automation, and expansion of applications across clinical diagnostics, pharmaceutical research, biotechnology, and cell and gene therapy.
Global Flow Cytometry Market Competitive Landscape
The Global Flow Cytometry Market is increasingly technology-driven and application-oriented, with companies focusing on multiparameter flow cytometry, spectral flow cytometry, cell sorting, high-parameter analysis, automated workflows, nanoscale particle analysis, reagents and consumables, software, and integrated cell-analysis solutions. Key players include Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Danaher Corporation, Agilent Technologies, Miltenyi Biotec GmbH, Bio-Rad Laboratories Inc., Merck KGaA, Sysmex Corporation, Sony Biotechnology Inc., Cytek Biosciences Inc., Bio-Techne Corporation, BioLegend Inc., and Sartorius AG. Competition is shaped by instrument sensitivity, fluorescence detection capabilities, multiparameter analysis, automation, data-analysis software, workflow efficiency, application-specific solutions, product innovation, R&D investment, strategic collaborations, acquisitions, and expansion into clinical diagnostics, oncology, immunology, pharmaceutical research, and cell and gene therapy applications.
Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/29653/
Flow Cytometry Market, Key Players
Thermo Fisher Scientific, Inc.Becton, Dickinson and CompanyDanaher CorporationAgilent TechnologiesLuminex CorporationMiltenyi Biotec GmbHBio-Rad Laboratories, Inc.Merck KGaASysmex CorporationSony Biotechnology Inc.Stratedigm, Inc.Cytek Biosciences, Inc.Bio-Techne CorporationBioLegend, Inc.Sartorius AGApogee Flow SystemsThermoGenesis Holdings, Inc.Nexcelom Bioscience LLCUnion Biometrica, Inc.De Novo Software
Frequently Asked Questions:
What segments are covered in the Global Market report?
Ans. The segments covered in the Market report are based on Product & Service, By Technology Type, By End-use, and End-Use Industry.
Which region held the largest Market share in 2025?
Ans. The North America region held the largest Market share in 2025.
What is the expected Market size by 2032?
Ans. The Flow Cytometry Market size is expected to reach USD 11.14 Bn by 2034.
What was the key driver of the Global Flow Cytometry Market?
Ans. The factors driving the market growth include the rising R&D investments in the biotechnology sector and technological advancements in the field of flow cytometry for introducing new and improved analytical tools, such as microfluidic flow cytometry, for point-of-care testing.
What is the expected CAGR of the Global Market during the forecast period?
Ans. The expected CAGR of the Market is 9% during the forecast period.
Analyst Perspective
Analysts highlight that the Global Flow Cytometry Market is being driven by growing adoption of multiparameter cellular analysis across clinical diagnostics, oncology, immunology, cancer research, drug discovery, and life science research. Advances in spectral flow cytometry, high-parameter analysis, cell sorting, automation, and data-analysis software are expanding market applications. At the same time, high instrument and operating costs, complex workflows, and the shortage of skilled professionals remain key challenges. Growing research in single-cell analysis, immunotherapy, stem-cell studies, and cell and gene therapy, along with increasing pharmaceutical and biotechnology R&D, is creating new opportunities and expected to shape the market through 2034.
Related Reports:
Flow Cytometry Products Market by Technology, Modality, Component Type, End-Use, and Product – Global Forecast to 2034
Cell Sorting Market by Product, Technology, Cell Type, Cell Size, Application, End-User, and Region – Global Forecast to 2034
Cell Analysis Market by Product & Service, Technique, Process, End-User, and Region – Global Forecast to 2034
Cell Analysis Instruments Market by Panel Type, Application, End-User, and Region – Global Forecast to 2034
Single Cell Analysis Market by Product, Application, Technique, End-User, and Region – Global Forecast to 2034
About Maximize Market Research – Global Flow Cytometry Market
Maximize Market Research is a leading global market research and business consulting firm delivering data-driven insights across the Healthcare, Pharmaceuticals, Life Sciences, Biotechnology, and Medical Technology sectors, including the Global Flow Cytometry Market. Its research helps businesses understand evolving market trends, assess market dynamics, identify emerging opportunities, and evaluate developments across flow cytometry instruments, reagents and consumables, software, cell analysis technologies, spectral flow cytometry, and automated laboratory workflows.
Expertise in Flow Cytometry & Life Science Research
With expertise in healthcare, biotechnology, pharmaceuticals, and life sciences market research, Maximize Market Research provides insights into flow cytometry systems, cell-based and bead-based flow cytometry, multiparameter cellular analysis, immunophenotyping, cell sorting, spectral flow cytometry, high-parameter analysis, and advanced data-analysis solutions. Its research evaluates market trends, technological developments, clinical applications, R&D activities, product launches, competitive developments, and emerging applications across oncology, immunology, drug discovery, cell-based research, and cell and gene therapy, helping industry stakeholders identify growth opportunities across the global flow cytometry ecosystem.
Contact:
Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+91 96073 65656
Email: sales@maximizemarketresearch.com
Content Source: https://www.maximizemarketresearch.com/market-report/flow-cytometry-market/29653/
Visit Our Web Site: https://www.maximizemarketresearch.com/
LinkedIn.com: https://www.linkedin.com/company/maxmize-market-research-pvt-ltd/
Instagram: https://www.instagram.com/maximizemarketresearch/
Facebook: https://www.facebook.com/maximizemarketresearch/
X (Twitter): https://x.com/MMRAnalytics
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/global-flow-cytometry-market-to-reach-usd-11-14-billion-by-2034-at-9-cagr-as-rising-adoption-in-clinical-diagnostics-growing-multiparameter-cell-analysis-and-advances-in-high-parameter-flow-cytometry-accelerate-market-growth-r-302887663.html
You may like
Technology
OpenText Announces Pricing of Senior Secured Notes Offering to Redeem its Outstanding 2027 Notes and Fund Tender Offer for a Portion of its Outstanding 2028 Notes
Published
50 minutes agoon
September 23, 2026By
WATERLOO, ON, Sept. 23, 2026 /PRNewswire/ — Open Text Corporation (the “Company” or “OpenText”) (NASDAQ: OTEX), (TSX: OTEX) today announced that it has priced an offering (the “Notes Offering”) of $500 million principal amount of 6.700% senior secured notes due 2031 and $500 million principal amount of 7.150% senior secured notes due 2033 (together, the “Notes”).
The Notes will be guaranteed on a senior secured basis by OpenText’s existing wholly-owned subsidiaries that are guarantors or co-obligors under OpenText’s senior secured credit facilities, term loan credit agreement and its 6.900% Senior Secured Notes due 2027 (the “2027 Notes”). The Notes and related guarantees will be secured on the same basis as the Company’s senior secured credit facilities, term loan credit agreement and 2027 Notes. The Notes Offering is expected to close on October 1, 2026, subject to customary closing conditions.
OpenText intends to use the net proceeds from the Notes Offering, together with cash on hand, to fund, in the aggregate (i) the redemption in full of the outstanding $1.0 billion principal amount of its 2027 Notes, including the payment of the applicable redemption premium, accrued and unpaid interest and related costs and expenses and (ii) the consideration for any of its outstanding 3.875% Senior Notes due 2028 (the “2028 Notes”) accepted for purchase in the tender offer by the Company for such 2028 Notes, up to an aggregate principal amount of the 2028 Notes that will not exceed $450 million (subject to increase or decrease by the Company), plus accrued and unpaid interest and related costs and expenses (the “Tender Offer”).
The Notes and related guarantees will not be registered under the Securities Act of 1933, as amended (the “Securities Act”). The Notes and the related guarantees are being issued pursuant to Rule 144A and Regulation S under the Securities Act. The Notes and related guarantees may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act), except to persons reasonably believed to be qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act and to certain persons in offshore transactions in reliance on Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, qualification or exemption under the securities laws of any such jurisdiction.
This press release shall not constitute a notice of redemption under the indenture governing the 2027 Notes, and such redemption is subject to the conditions set forth in the applicable notice of redemption, including the financing condition described therein. Such notice has been made only in accordance with the provisions of the indenture governing the 2027 Notes. There can be no assurances as to whether any such redemption will be effected as described above.
This press release shall not constitute an offer to purchase the 2028 Notes in the Tender Offer, which is only made pursuant to the Offer to Purchase dated September 23, 2026 (the “Offer to Purchase”), which is subject to the conditions, including the financing condition described therein. Holders of the 2028 Notes should refer to the Offer to Purchase available from Global Bondholder Services Corporation, the tender and information agent for the Tender Offer, and the Company’s concurrent press release related to the Tender Offer dated September 23, 2026.
OTEX-F
About OpenText
OpenText™ is a global leader in data management for enterprise AI, helping organizations protect, govern, and activate their data with confidence. Our technologies turn data into information with context to form the knowledge base for enterprise AI.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release may contain words considered forward-looking statements or information under applicable securities laws. These statements are based on OpenText’s current expectations, estimates, forecasts and projections about the Notes Offering, the proposed conditional redemption and the proposed Tender Offer, and the operating environment, economies and markets in which OpenText operates. These statements are subject to important assumptions, risks and uncertainties that are difficult to predict, and the actual outcome may be materially different. OpenText’s assumptions, although considered reasonable by OpenText at the date of this press release, may prove to be inaccurate and consequently its actual results could differ materially from the expectations set out herein. For additional information with respect to risks and other factors which could occur, see OpenText’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other securities filings with the Securities and Exchange Commission and other securities regulators. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Unless otherwise required by applicable securities laws, OpenText disclaims any intention or obligations to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Copyright © 2026 OpenText. All Rights Reserved. Trademarks owned by OpenText. One or more patents may cover this product(s).
View original content to download multimedia:https://www.prnewswire.com/news-releases/opentext-announces-pricing-of-senior-secured-notes-offering-to-redeem-its-outstanding-2027-notes-and-fund-tender-offer-for-a-portion-of-its-outstanding-2028-notes-302888261.html
SOURCE Open Text Corporation
Technology
Everpure’s Expanding Business Model Fuels New Long-Term Outlook
Published
50 minutes agoon
September 23, 2026By
Company outlines path for durable, accelerated growth through four strategic growth vectors
SANTA CLARA, Calif., Sept. 23, 2026 /PRNewswire/ — Today at its 2026 Financial Analyst Meeting, Everpure (NYSE: P), the company revolutionizing storage and data management, provided details on its business expansion providing durable, accelerated growth. The company also reaffirmed its fiscal year 2027 outlook and provided a preliminary outlook for fiscal year 2028.
“Everpure is at an inflection point as we expand our horizons to managing data in the enterprise and solutions for hyperscalers,” said Charlie Giancarlo, Chairman and Chief Executive Officer at Everpure. “A decade of committed investment in an integrated, extensible architecture has created a structurally higher growth baseline in our core business. This same core IP has unlocked three distinct, incremental markets—allowing us to expand our opportunity, drive significant operating leverage, and provide enhanced visibility into our long-term financial trajectory.”
Sustained R&D Innovation
Over the past five years, Everpure has consistently dedicated on average 19% of annual revenue to R&D1. Everpure’s focused R&D investments on a single, unified platform is a superior use of invested capital versus fragmenting resources across multiple legacy architectures. This disciplined strategy has fueled both the durability of Everpure’s core business, demonstrated by eight consecutive quarters of accelerating revenue growth, and its expansion into new high growth markets. Building upon a track record of consistent market share gains across both inflationary and deflationary cycles, Everpure expects its strong R&D leadership to extend its product velocity while accelerating penetration into new growth markets.
__________________
1On a non-GAAP basis. For a reconciliation to GAAP, please see the table at the end of this release.
Four Strategic Growth Vectors
By leveraging its proprietary intellectual property and extensible architecture, Everpure has unlocked multiple new distinct market opportunities alongside its core foundation. The company outlined four strategic growth vectors:
Core and Core AI: Includes FlashBlade, Flash Array, and Evergreen//One subscriptions, both CPU- and GPU-attached.Modern Data Software: Includes Everpure Data Intelligence, Everpure Data Stream, Portworx, Everpure Resilience, and Everpure Cloud.Scale AI: Includes FlashBlade//EXA solutions tailored for neoclouds and AI-native providers.Hyperscale Solutions: Includes DirectFlash technology designed specifically for hyperscalers.
Core and Core AI is projected to continue to gain market share, and the three new growth vectors—Modern Data Software, Scale AI, and Hyperscale Solutions—are expected to represent approximately 20% of total revenue by fiscal year 2030.
Financial Outlook and Capital Management
“Everpure’s financial profile is durably resetting to higher levels of growth and profitability,” said Tarek Robbiati, Chief Financial Officer at Everpure. “We have demonstrated over the past decade-plus that we can profitably grow and take share in our core business across inflationary and deflationary cycles. This has been made possible by our unique differentiated IP which is now enabling a sustained level of financial performance well above Rule of 40.”
To support this trajectory, Everpure maintains a disciplined capital management framework centered on funding organic investment, strengthening the balance sheet, pursuing strategic mergers and acquisitions, completing share buybacks to offset dilution from stock-based compensation, and executing additional select buybacks to return excess capital. Today’s new framing preserves flexibility to fund a much larger opportunity set than the company has ever had.
The company re-affirmed its fiscal year 2027 revenue and operating income guidance provided on its second quarter fiscal year 2027 earnings call, and provided a preliminary outlook for fiscal year 2028.
FY27 Guidance
Revenue
$5.03B to $5.07B
Revenue YoY Growth Rate
37% to 38%
Non-GAAP Operating Income
$940M to $960M
Non-GAAP Operating Income YoY Growth Rate
48% to 51%
Preliminary FY28 Outlook
Revenue
$7.0B to $7.3B
Revenue YoY Growth Rate
39% to 45%
Non-GAAP Operating Income
$1.7B to $1.9B
Non-GAAP Operating Income YoY Growth Rate
80% to 100%
These statements are forward-looking and actual results may differ materially. Refer to the Forward Looking Statements section below for information on the factors that could cause our actual results to differ materially from these statements.
Additional Resources
Executive Commentary: Read additional insights on Everpure’s market expansion and differentiated value for hyperscalers.Webcast Replay and Presentation Slides: The Financial Analyst Meeting webcast replay and presentation slides will be available in the Events & Presentations section of Everpure’s Investor Relations website.
About Everpure
Everpure (NYSE: P) allows organizations to take control of their data with an industry-leading, ever-evolving storage and data management platform. We help companies unleash the power of their data by ensuring it is accessible, intelligent, and ready to perform in the AI era. We make data management effortless while simultaneously scaling performance and significantly reducing energy consumption. With one of the highest Net Promoter Scores for over a decade, Everpure is the choice of the world’s most innovative organizations. For more information, visit www.everpuredata.com.
The release timing of any discussed functionality remains at Everpure’s sole discretion. The information provided is not a commitment to deliver discussed functionality based on any timeline.
Investors and others should note that we announce material business and financial information through our investor relations website at investor.everpuredata.com, SEC filings, public conference calls and webcasts, and press releases, including earnings press releases. We also announce business and financial information through our newsroom website (https://www.everpuredata.com/company/newsroom.html), blog (http://blog.everpuredata.com), LinkedIn (linkedin.com/company/everpure-data), X (x.com/EverpureData), Facebook (@purestorage), Instagram (@purestorage) and YouTube (@everpure-data). It is possible that the information we post on these channels could be deemed to be material information. Therefore, we encourage investors to follow these channels, in addition to our SEC filings, public conference calls and webcasts, and press releases.
Forward Looking Statements
This press release contains forward-looking statements regarding our products, business, operations and financial performance, including but not limited to our views relating to our future period financial and business results, our expectations regarding rule of 40, and the expected contribution to our revenue from modern data software, scale AI, and hyperscale products; our capital allocation priorities, including research and development investment, strategic mergers and acquisitions and the return of excess capital; our total addressable and serviceable addressable market estimates and our expectations regarding market growth and continued market share gains, including Core and Core AI; the expected mix of core and new product revenue; demand for our products and subscription and consumption offerings, including Evergreen//One, and the related sales mix; our sales pipeline and the timing and magnitude of large orders, including sales to hyperscalers and large enterprises; our technology and product strategy and roadmap, including DirectFlash, FlashBlade//EXA, the Enterprise Data Cloud and our expansion into data intelligence; our market opportunities in modern data software, scale AI and hyperscale environments, our ability to meet hyperscalers’ performance, price and other requirements, to expand with existing and land new hyperscale customers, and the timing and amount of hyperscale revenue; our ability to manage supply chain disruptions and procure sufficient flash and other components; the impact of component cost increases and NAND pricing cycles on our pricing, gross margin and share gains; the anticipated effects of our acquisition of 1touch; our expectations regarding product and technology differentiation, sustainability and energy savings for customers, new investments and partnerships; and the impact of inflation, currency fluctuations, tariffs or other adverse economic conditions.
Actual results may differ materially from the results predicted. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the caption “Risk Factors” and elsewhere in our filings and reports with the U.S. Securities and Exchange Commission, which are available on our Investor Relations website at investors.everpuredata.com and on the SEC website at www.sec.gov. Additional information is also set forth in our Annual Report on Form 10-K for the fiscal year ended February 1, 2026. All information provided in this release and in the attachments is as of September 23, 2026, and Everpure undertakes no duty to update this information unless required by law.
Non-GAAP Financial Measures
To supplement its guidance, Everpure has provided forward-looking guidance on non-GAAP operating income and the related year-over-year growth rate for fiscal year 2027 and, on a preliminary basis, for fiscal year 2028. Everpure has also provided average non-GAAP research and development expense as a percentage of revenue for the five fiscal years ended February 1, 2026. Non-GAAP research and development expense excludes certain expenses such as stock-based compensation expense, payments to former shareholders of acquired companies, payroll tax expense related to stock-based activities, expenses for severance and termination benefits related to workforce realignment, and duplicate lease costs during the transition of our corporate headquarters. For a reconciliation of average non-GAAP research and development expense as a percentage of revenue for the five fiscal years ended February 1, 2026 as a percentage of revenue for the same period, please see the table at the end of this press release.
Everpure uses these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding Everpure’s performance by excluding certain expenses that may not be indicative of its ongoing core business operating results, and that both management and investors benefit from referring to these non-GAAP financial measures in assessing performance and when planning, forecasting, and analyzing future periods. The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for financial results prepared in accordance with GAAP, and Everpure’s non-GAAP measures may be different from non-GAAP measures used by other companies.
Everpure has not reconciled its guidance for non-GAAP operating income and the related year-over-year growth rate to their most directly comparable GAAP measures because certain items that impact these measures are not within Everpure’s control and/or cannot be reasonably predicted. Accordingly, reconciliations of these non-GAAP financial measures guidance to the corresponding GAAP measures are not available without unreasonable effort.
Everpure calculates the Rule of 40 as year-over-year revenue growth rate + non-GAAP operating margin.
Reconciliation from GAAP research and development expense results to the comparable non-GAAP measures (in thousands except percentages, unaudited):
Fiscal Year Ending
2026
2025
2024
2023
2022
Research and development expense (GAAP)
$ 963,291
$ 804,405
$ 736,764
$ 692,528
$ 581,935
Less: Stock-based compensation expense
(238,021)
(201,058)
(167,294)
(161,694)
(142,264)
Less: Payments to former shareholders of acquired companies
—
—
(2,323)
(5,820)
(17,178)
Less: Payroll tax related to stock-based activities
(9,635)
(10,154)
(6,941)
(6,402)
(4,889)
Less: Expenses for severance and termination benefits related
to workforce realignment
(2,164)
—
—
—
—
Less: Duplicate lease costs during the transition of our
corporate headquarters
—
—
(3,907)
(5,823)
—
Research and development expense (non-GAAP)
$ 713,471
$ 593,193
$ 556,299
$ 512,789
$ 417,604
Total revenue (GAAP)
$ 3,662,843
$ 3,168,164
$ 2,830,621
$ 2,753,434
$ 2,180,848
% of total revenue (GAAP)
26 %
25 %
26 %
25 %
27 %
Fiscal 2026 5-year average % of total revenue (GAAP)
26 %
% of total revenue (non-GAAP)
19 %
19 %
20 %
19 %
19 %
Fiscal 2026 5-year average % of total revenue (non-GAAP)
19 %
View original content to download multimedia:https://www.prnewswire.com/news-releases/everpures-expanding-business-model-fuels-new-long-term-outlook-302888106.html
SOURCE Everpure
Technology
BlueGreen Alliance Marks 20th Anniversary at Climate Week
Published
50 minutes agoon
September 23, 2026By
WASHINGTON, Sept. 23, 2026 /PRNewswire/ — Leaders and advocates gathered in New York for Climate Week heard the unique story of the BlueGreen Alliance (BGA) during a panel discussion on worker-powered climate action. BGA—celebrating the 20th anniversary of its founding—was joined by Sen. Brian Schatz (D-HI), United Steelworkers (USW) International President Roxanne Brown, and Natural Resources Defense Council (NRDC) Action Fund President Manish Bapna.
The panel discussion explored the lessons that can be learned from BGA’s 20 years of proven success as the only national coalition of environmental and labor organizations in the world. The organization—founded in 2006 by former USW International President Leo Gerard and former Executive Director of the Sierra Club Carl Pope—is aligned on the shared belief that we don’t have to choose between good jobs and a clean environment. We can and must have both.
“I have worked with BGA since its infancy, and I remain committed to the mission of this organization,” said USW International President and BGA Co-Chair Roxanne Brown. “Working with our environmental partners to deepen understanding across our movements gives us the footing we need to enact real change that will build a better future for working families for generations to come.”
The panelists discussed BGA’s continued work to leverage the collective strength of its partners and their members to build consensus and advocate for shared solutions that fight the climate crisis, create good-paying union jobs, advance racial and economic justice, and protect the health and fundamental rights of working people.
“As a coalition, BGA has struck significant wins for the environmental and labor movements, but much of that progress has been under attack in recent years. That is why the enduring strength of our coalition is so important,” said NRDC Action Fund President and BGA Board Member Manish Bapna. “We remain dedicated to working in partnership to build on our successes and grow a clean economy built with good union jobs.”
“Economic change in recent decades has been driven by elites and working people have not seen the benefits. Unless working people are at the center of climate policy and energy transition, the solutions won’t work for them, and they won’t stick.” said BlueGreen Alliance Executive Director Jason Walsh. “In the face of an escalating climate crisis and rising inequality, our work is more urgent than ever. These crises can only be confronted by worker-powered climate action, and that is the work BGA plans to carry forward over the next 20 years.”
View original content to download multimedia:https://www.prnewswire.com/news-releases/bluegreen-alliance-marks-20th-anniversary-at-climate-week-302888273.html
SOURCE BlueGreen Alliance
OpenText Announces Pricing of Senior Secured Notes Offering to Redeem its Outstanding 2027 Notes and Fund Tender Offer for a Portion of its Outstanding 2028 Notes
Everpure’s Expanding Business Model Fuels New Long-Term Outlook
BlueGreen Alliance Marks 20th Anniversary at Climate Week
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology3 days agoMCP Is the New NDC — Is This Travel’s Shift-to-Streaming Moment?
-
Technology3 days agoNew IBM CHRO Study: AI Puts Critical Thinking at the Center of Workforce Priorities
-
Technology5 days agoPeoplevine Secures Multi-Million-Dollar Growth Investment to Accelerate AI-Powered Hospitality
-
Technology1 day agoAnde Raises $52M Seed and Series A to Launch The First Entertainment Operating System For Enterprises
-
Technology20 hours agoReap and Visa Collaborate to Launch Stablecoin Card Programs Across 100+ Markets
-
Technology1 day agoCognex to Acquire RealSense, Expanding Machine Vision Leadership into High-Growth Robotic Perception Market
-
Technology3 days ago01F Group Announces Investment in DANA, Indonesia’s Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia’s Fintech Opportunity
-
Technology2 days agoFluxnium Secures $7 Million Seed Round to Build a New Domestic Supply of Uranium
